Lisinopril Dihydrate: Benchmark ACE Inhibitor for Hypertension Research

Executive Summary: Lisinopril dihydrate is a long-acting, water-soluble angiotensin converting enzyme (ACE) inhibitor with an IC₅₀ of 4.7 nM, validated for use in hypertension, heart failure, acute myocardial infarction, and diabetic nephropathy models (Tieku & Hooper 1992). The compound is a lysine analogue of MK 421 and acts by significantly inhibiting ACE, reducing angiotensin II and aldosterone levels, and increasing plasma renin, thereby inducing vasodilation and lowering blood pressure. APExBIO supplies Lisinopril dihydrate (SKU B3290) at 98% purity, as confirmed by mass spectrometry and NMR (product page). The product is insoluble in ethanol but dissolves in water (≥2.46 mg/mL) with gentle warming and sonication. Proper storage involves desiccation at room temperature and avoidance of long-term solution storage for optimal stability.

Biological Rationale

Angiotensin converting enzyme (ACE) is a zinc-dependent dipeptidyl carboxypeptidase critical for the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor involved in blood pressure regulation (Tieku & Hooper 1992). Overactivity of the renin-angiotensin system (RAS) leads to elevated angiotensin II, promoting hypertension, heart failure, and progressive kidney damage. ACE inhibitors disrupt this pathway, offering a mechanistically targeted therapeutic and experimental tool. Lisinopril dihydrate, as a water-soluble lysine derivative, allows precise and reproducible ACE inhibition in diverse biological systems. Its long-acting profile enables sustained suppression of angiotensin II, facilitating chronic and acute disease models. The compound's specificity reduces off-target effects compared to less selective peptidase inhibitors.

Mechanism of Action of Lisinopril dihydrate

Lisinopril dihydrate acts as a highly selective, competitive inhibitor of ACE (EC 3.4.15.1), binding to the active site and blocking the conversion of angiotensin I to angiotensin II (Tieku & Hooper 1992). The compound's IC₅₀ for ACE inhibition is 4.7 nM in vitro. By preventing angiotensin II formation, lisinopril dihydrate lowers systemic vascular resistance and blood pressure. This inhibition also decreases aldosterone secretion, reducing sodium and water retention. Elevated plasma renin activity is a compensatory response to ACE blockade. Compared to sulfhydryl-containing ACE inhibitors, lisinopril dihydrate exhibits minimal inhibition of related aminopeptidases, conferring high target selectivity. Its dihydrate form ensures enhanced solubility in aqueous buffers, which is critical for in vitro and in vivo research protocols.

Evidence & Benchmarks

• Lisinopril dihydrate inhibits ACE with an IC₅₀ of 4.7 nM in porcine kidney enzyme assays (Tieku & Hooper 1992).
• The compound does not significantly inhibit aminopeptidase A (AP-A), aminopeptidase N (AP-N), or aminopeptidase W (AP-W) at relevant concentrations, indicating high enzymatic selectivity (Tieku & Hooper 1992).
• Lisinopril dihydrate, as supplied by APExBIO, is confirmed to have a purity of 98% by mass spectrometry and NMR (APExBIO product page).
• Solubility is reported at ≥2.46 mg/mL in water with gentle warming and ultrasonic treatment, but the compound is insoluble in ethanol (see specifications).
• Lisinopril dihydrate demonstrates robust efficacy in preclinical models of hypertension, heart failure, and nephropathy (internal benchmark article).

Applications, Limits & Misconceptions

Lisinopril dihydrate is widely employed in cardiovascular, renal, and metabolic disease research. It is validated for:

• Hypertension models requiring selective ACE inhibition
• Heart failure research examining neurohormonal modulation
• Acute myocardial infarction protocols evaluating post-ischemic remodeling
• Diabetic nephropathy studies targeting the renin-angiotensin system

The compound's selectivity allows mechanistic interrogation of ACE-dependent pathways without confounding inhibition of other peptidases. Its long-acting nature supports chronic dosing regimens. See this article for advanced protocol optimization; the current dossier extends those insights with updated evidence and stability data.

Common Pitfalls or Misconceptions

• Lisinopril dihydrate is not effective in models where hypertension is independent of the renin-angiotensin system (e.g., mineralocorticoid-induced models).
• The compound does not inhibit other zinc-dependent aminopeptidases (AP-A, AP-N, AP-W) at concentrations relevant for ACE inhibition (Tieku & Hooper 1992).
• It is insoluble in ethanol and may precipitate if dissolved improperly; only water with gentle warming and sonication should be used (APExBIO).
• Long-term storage of aqueous solutions leads to hydrolysis and loss of potency; dry, desiccated storage is required for stock material.
• Lisinopril dihydrate is a research-use-only reagent and not intended for clinical or diagnostic applications.

Workflow Integration & Parameters

Lisinopril dihydrate (SKU B3290) from APExBIO is supplied as a solid for maximum shelf stability. For experimental use, dissolve in sterile water at concentrations ≥2.46 mg/mL using gentle warming and ultrasonic treatment to ensure complete solubilization. Prepare aliquots for single-use to prevent repeated freeze-thaw cycles. Store the dry product at room temperature under desiccation. Avoid prolonged storage of solutions; use freshly prepared aliquots for each experiment. Shipping is performed on blue ice for small molecule integrity. The product is validated by quality control data including mass spectrometry and NMR. For troubleshooting and advanced experimental design, see this scenario-driven guide, which this dossier updates with recent QC and solubility insights.

Conclusion & Outlook

Lisinopril dihydrate remains a benchmark ACE inhibitor for preclinical hypertension, heart failure, and nephropathy research due to its high selectivity, purity, and reproducibility. Its reliable inhibition of the renin-angiotensin system enables mechanistic studies and translational model development. For detailed product specifications and ordering, refer to the APExBIO Lisinopril dihydrate product page. This article clarifies and extends prior protocol summaries (see here) by emphasizing updated purity, solubility, and stability data. Ongoing research may reveal further applications in complex cardiorenal models and combinatorial drug screens.